Top > Quick Search > Search International Patent > DATA ACQUISITION METHOD FOR DETERMINING WHETHER CELL CYCLES OF KIDNEY-DERIVED CELLS IN SUBJECT HAVE PROGRESSED FROM G2 PHASE TO M PHASE, AND USE FOR SAME

DATA ACQUISITION METHOD FOR DETERMINING WHETHER CELL CYCLES OF KIDNEY-DERIVED CELLS IN SUBJECT HAVE PROGRESSED FROM G2 PHASE TO M PHASE, AND USE FOR SAME NEW_EN commons

Foreign code F190009992
File No. (FU789)
Posted date Oct 30, 2019
Country WIPO
International application number 2019JP009522
International publication number WO 2019188151
Date of international filing Mar 8, 2019
Date of international publication Oct 3, 2019
Priority data
  • P2018-066043 (Mar 29, 2018) JP
Title DATA ACQUISITION METHOD FOR DETERMINING WHETHER CELL CYCLES OF KIDNEY-DERIVED CELLS IN SUBJECT HAVE PROGRESSED FROM G2 PHASE TO M PHASE, AND USE FOR SAME NEW_EN commons
Abstract A data acquisition method according to the present invention is used for the purpose of using a clinical urine sample to simply and noninvasively detect whether the cell cycles of kidney-derived cells have progressed from the G2 phase to the M phase. This data acquisition method is for determining whether the cell cycles of kidney-derived cells in a subject have progressed from the G2 phase to the M phase and includes a step for detecting thioredoxin in urine collected from the subject.
Outline of related art and contending technology BACKGROUND ART
Renal failure, morbidity, and, a poor prognosis of diseases and, particularly, severe acute renal failure (acute kidney injury: AKI) is, the mortality rate is greater than 50%.
Conventionally, kidney failure (for example, acute renal failure) diagnosis, an amount of change in serum creatinine, and/or, based on the change in the amount of urine are carried out. However, the serum creatinine, renal failure 2-3 days occurs after the change from the amount for the biomarker, based on the change in the amount of serum creatinine diagnosed of renal impairment, delay the beginning of the treatment of renal impairment, as a result, tends to be a poor prognosis.
Therefore, when a failure occurs in an early stage renal from the resulting change in the amount of the biomarker and, L-FABP(L type fatty acid binding protein), NGAL(neutrophil gelatinase associated lipocalin), TIMP-2(tissue inhibitor of metalloproteinase-2), IGFBP7(insulin-like growth factor-binding protein 7), renal dysfunction (for example, acute renal failure) are used to diagnose (see Non-Patent Document 1 and 2). TIMP-2, and, is IGFBP 7, from G1 phase to phase S from renal cell in the cell cycle progression of the presence or absence of the biomarker can be detected.
Incidentally, in recent years, acute renal failure from the transition of chronic kidney disease, kidney epithelial cells from the G2 phase of cell cycle progression to the phase M is stopped and, from stage G2 to stage in the kidney epithelial cells M with the stop of the cell cycle progression of the tubules and interstitial fibrosis, is related has been suggested (see Non-Patent Document 3).
Scope of claims (In Japanese)[請求項1]
 被検体から採取した尿中のチオレドキシンを検出する工程を含む、被検体における腎由来細胞のG 2期からM期への細胞周期の進行の有無を診断するためのデータの取得方法。

[請求項2]
 被検体から採取した尿中のチオレドキシンを検出するための部材を備えている、被検体における腎由来細胞におけるG 2期からM期への細胞周期の進行の有無を診断するためのキット。

[請求項3]
 被検体から採取した尿中のチオレドキシンを検出する工程を含む、被検体における腎障害の回復または慢性化を予測するためのデータの取得方法。

[請求項4]
 上記慢性化は、腎由来細胞におけるG 2期からM期への細胞周期の停止に伴う尿細管間質の線維化を介した慢性化である、請求項3に記載のデータの取得方法。

[請求項5]
 被検体から採取した尿中のチオレドキシンを検出するための部材を備えている、被検体における腎障害の回復または慢性化を予測するためのキット。

[請求項6]
 上記慢性化は、腎由来細胞におけるG 2期からM期への細胞周期の停止に伴う尿細管間質の線維化を介した慢性化である、請求項5に記載のキット。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • UNIVERSITY OF FUKUI
  • JJAPAN BIOSTRESS RESEARCH PROMOTION ALLIANCE
  • Inventor
  • KASUNO, Kenji
  • IWANO, Masayuki
  • YODOI,Junji
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close